the 4th annualclinical genome tcgc … · new york genome center nathan d. price, ... 4:00...

Register by February 20for Early-Bird Savings up to $550

Final Agenda

Organized byCambridge Healthtech Institute ClinicalGenomeConference.com

Corporate Sponsor: Co-Sponsored by:

June 22-24, 2015 • Hotel Kabuki • San Francisco, CA

Join your peers and colleagues to share new findings and solutions for advancing the applications of clinical genome medicine.

The Clinical Genome Conference sparks vital discussion of applications, questions and solutions surrounding clinical genome analysis between scientists, physicians, diagnosticians, genetic counselors, bioinformaticists,

ethicists, regulators, insurers, lawyers and administrators.

Nathaniel Pearson, Ph.D.

New York Genome Center

Nathan D. Price, Ph.D.

Institute for Systems Biology

Laura J. van ’t Veer, Ph.D.

University of California, San Francisco

• Big Data Translating Healthcare

• Guiding Cancer Care

• Understanding “Wellness”

CLINICAL SEQUENCING:A GOOD INVESTMENT?

KEYNOTE SPEAKERS

TCGCTHE 4th ANNUAL

CLINICAL GENOMECONFERENCE Mining the Genome for Medicine

PRE-CONFERENCESHORT COURSE* CONFERENCE AGENDA

The reliability, robustness and reproducibility of next-generation sequencing platforms are no longer questioned, making the unstoppable march of genomics into clinical practice a reality. However, many challenges remain for the successful translation of genomic knowledge into health advances and clinical utility.

Bio-IT World and Cambridge Healthtech Institute are again proud to host the Fourth Annual TCGC: The Clinical Genome Conference, inviting stakeholders impacting clinical genomics to share new findings and solutions for advancing the applications of clinical genome medicine.

MONDAY, JUNE 22

9:00 am Short Course Registration and Morning Coffee

10:00 am-1:00 pm Short Course

2:00 Conference Registration

3:00 Chairperson’s Opening RemarksEric Holland, M.D., Ph.D., Director, Solid Tumor Translational Research, Fred Hutchinson Cancer Research Center

KEYNOTE SESSION

3:15 Through the Keyhole to Genomic Wonderland: Common Sense, Beyond Uncommon NonsenseNathaniel Pearson, Ph.D., Senior Director, Scientific Engagement & Public Outreach, New York Genome CenterOne hundred fifty years after Gregor Mendel first systematically probed genetic heritability, we risk forgetting a key insight from his work, in our rush to broaden clinical genomics from urgent diagnosis for a few to lifelong care for all. By fully embracing that insight now, we can wisely bolster our health infrastructure for the long haul.

4:00 Integrating the Principles of Preventative and Personalized Medicine to Advance WellnessNathan D. Price, Ph.D., Associate Director, Institute for Systems BiologyFuture medicine will be more proactive and data-rich than anything before possible – and will focus on maintaining and enhancing wellness more than just reacting to disease. We have launched a large-scale 100K wellness project that integrates genomics, proteomics, transcriptomics, microbiomes, clinical chemistries and wearable devices to monitor wellness and disease. I will present results from our pilot study of 107 individuals, showing how this data led to actionable findings for individuals to improve health and reduce risk drivers of disease.

4:45 Big Data in Translational Cancer GenomicsLaura J. van ’t Veer, Ph.D., Director, Applied Genomics and Angela and Shu Kai Chan Endowed Chair, Cancer Center, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San FranciscoMolecular genomics contributes to the knowledge of who is at risk to develop cancer, how external factors may influence this risk, whether tumors are likely to metastasize or not, and which subtype of tumors will likely respond to what therapy. Dr. van ’t Veer’s current research involves integrating various types of genomics data, including next-generation sequencing big data, and is aimed at understanding the molecular basis for early response to therapy as a surrogate for long-term survival prediction.

5:30 Welcome Reception in the Exhibit Hall with Poster Viewing

6:30 Close of Day

MONDAY, JUNE 22

9:00 am Short Course Registration

10:00 am-1:00 pm

Personal Genomics: Variant Analysis and Interpretation with Public DataIn this short course, we take a hands-on approach to learning about the power and limitations of current research, technology and public data sources to interpret the human genome of individuals outside of the clinical diagnosis context. By interactively analyzing my own exome and the genomes of other public genomes, the short course orients participants with programmatic analysis and interpretation techniques applicable to many contexts.

Learning Objectives:

1. How GWAS studies, price drops of NGS sequencing and the sharing of clinical classification of variants shape personal genomics.

2. Pros and cons of SNP arrays, whole-exome and whole-genome sequencing in the interpretation of the genetics of healthy individuals.

3. Public databases, websites and visualization tools for interpreting individuals’ genetic variants.

4. Hands-on case study of analyzing my own exome and other shared individual genomes, walking through the discrete steps to annotate, filter and explore variants of interest to an individual’s outlook and wellness.

5. How to spot false-positive variants at the aligned read level, and pull in multiple annotation sources to assess the bioinformatics evidence of a variant’s pathogenicity.

Instructors:Gabe Rudy, Vice President, Product & Engineering, Golden Helix KT Pickard, MBA, Founder, StartCodon

* Separate registration required

2 | ClinicalGenomeConference.com

TUESDAY, JUNE 23

7:00 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

Genomics Guiding Cancer Care8:00 Chairperson’s RemarksNathaniel Pearson, Ph.D., Senior Director, Scientific Engagement & Public Outreach, New York Genome Center

»8:05 FEATURED PRESENTATION: CIViC: CLINICAL INTERPRETATION OF VARIANTS IN CANCER

Malachi Griffith, Ph.D., Associate Director, The Genome Institute; Assistant Professor, Genetics, Washington University School of MedicineTo realize the potential of personalized medicine, genomic aberrations must be placed in the context of therapeutic response and diagnostic or prognostic associations. The evidence for these associations must be captured and characterized so that we can achieve a principled consensus among genomic experts, pathologists and oncologists on how best to interpret a genomic alteration in a clinical context. To this end, we present CIViC as a forum for the clinical interpretation of variants in cancer.

8:35 Identification of Independent Primary Tumors and Intrapulmonary Metastases Using DNA Rearrangements in Non-Small Cell Lung CancerGeorge Vasmatzis, Ph.D., Assistant Professor, Laboratory Medicine & Pathology, Mayo Clinic & FoundationDistinguishing independent primary tumors from intrapulmonary metastases in non-small cell carcinoma remains a clinical dilemma with significant clinical implications. Using next-generation DNA sequencing, we developed a chromosomal rearrangement-based approach to differentiate multiple primary tumors from metastasis. A total of 41 tumor samples were sequenced. Lung tumors predicted to be independent primary tumors based on different histologic subtype did not share any genomic rearrangements. Concordance between histology and genomic data occurred in the majority of cases. Discrepant cases were resolved by genome sequencing.

9:05 The Role of Genome Sequencing in Personalized Breast Cancer PreventionWeiva Sieh, M.D., Ph.D., Assistant Professor, Epidemiology, Department of Health Research and Policy, Stanford University School of MedicineThe benefits of genome sequencing for guiding personalized preventive strategies at the population level are uncertain. We evaluated the benefits and harms of targeting preventive efforts to the subpopulation of women whose genomes put them at highest risk of breast cancer using mathematical models for (1) 86 currently known breast cancer susceptibility alleles and (2) assuming complete knowledge of all breast cancer genes. Our findings suggest that genome sequencing has the potential to guide personalized breast cancer prevention, and that the benefits will improve with increased understanding of the genetic etiology of breast cancer.

9:35 Talk Title to be Announced Sponsored by

David Jackson, Ph.D., Chief Innovation Officer, Molecular Health

9:50 Sponsored Presentation (Opportunity Available)

10:05 Coffee Break in the Exhibit Hall with Poster Viewing

10:45 Integration of Genetic and Epigenetic Data to Understand Genetic Risk of Prostate CancerBogdan Pasaniuc, Ph.D., Assistant Professor, Pathology & Laboratory Medicine and Human Genetics, David Geffen School of Medicine, University of California, Los AngelesAlthough genome-wide association studies have identified over 100 genetic loci that increase risk for developing prostate cancer, their functional effects on risk remain largely unknown. I present new approaches that integrate large-scale genetic data with cell-type-specific epigenetic functional annotation data to gain insights into the genetic architecture of prostate cancer risk.

11:15 Ultrasensitive Detection of Circulating Tumor DNA by Deep SequencingMaximilian Diehn, M.D., Ph.D., Assistant Professor, Radiation Oncology, Stanford Cancer Institute, Institute for Stem Cell Biology & Regenerative Medicine, Stanford UniversityCirculating tumor DNA (ctDNA) represents a promising biomarker for detection and monitoring of cancers. Work on clinical applications of next-generation sequencing-based ctDNA quantitation will be discussed.


12:15 pm Session Break

12:30 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

Understanding “Wellness”2:00 Chairperson’s RemarksMalachi Griffith, Ph.D., Associate Director, The Genome Institute; Assistant Professor, Genetics, Washington University School of Medicine

2:05 An Approach to Whole-Genome Sequence as a Lifelong Health ResourceSek Won Kong, M.D., Assistant Professor, Medicine/Informatics Program, Harvard Medical School and Boston Children’s HospitalAccumulated genomic variants provide a foundation of information in the context of precision medicine, and an individual genome can be a resource for lifelong well being. To achieve analytical validity of whole-genome sequence for clinical use, a reproducible and accurate analysis and interpretation pipeline is required. Carrier status of disease-causing mutations and pharmacogenomic variants are of primary interest; however, estimating genetic liability for complex diseases using established risk alleles might be informative. We demonstrate how complex trait risk variants from an individual genome can be summarized and reported for the general clinician and patients.

2:35 Whole-Genome Sequencing of the World’s Oldest PeopleKristen Fortney, Ph.D., Research Scientist, Stuart K. Kim Laboratory, Developmental Biology, Stanford UniversitySupercentenarians (110 years or older) are the world’s oldest people. We sequenced the genomes of 17 supercentenarians to see if we could uncover the genetic basis for their extreme longevity. From this small sample size, we were unable to find rare protein-altering variants significantly associated with extreme longevity. We have made the complete genomes of all 17 supercentenarians available as a resource to assist discovery in future studies.


3:35 Refreshment Break in the Exhibit Hall with Poster Viewing

4:15 Understanding Deep Metagenomics Sequencing in Clinical SamplesArun Rawat, Ph.D., Bioinformatician II, Translational Genomics Research InstituteDecreasing cost of next-generation sequencing provides unique opportunities to identify host-associated microbial communities in clinical samples. Our goal is to understand the unknown etiologic agent in symptomatic patients to allow faster clinical decisions. Prediction of undiagnosed disease is possible with high reliability despite the variability in metagenomic samples and computational challenges.

4:45 Leveraging Germline Genomics to Improve an Individual’s HealthJohn S. Witte, Ph.D., Professor, Epidemiology & Biostatistics and Urology; Head, Division of Genetic and Cancer Epidemiology; Associate Director, Institute for Human Genetics; Co-Leader, Cancer Center Program in Cancer Genetics, University of California, San Francisco

5:15 Interactive Breakout Discussion GroupsWrap up the day with a moderated discussion group to brainstorm the translation of genomic technologies into the clinic. Use this opportunity to share new findings, propose solutions and develop collaborations with the diverse stakeholders advancing genomic medicine.

6:00 Close of Day

WEDNESDAY, JUNE 24

7:00 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

Clinical Sequencing: A Good Investment?8:00 Chairperson’s RemarksKatherine Tynan, Ph.D., Business Development & Strategic Consulting for Diagnostics Companies, Tynan Consulting LLC

8:05 Estimating the Cost Effectiveness of Returning Incidental Findings from Next-Generation Genomic SequencingCaroline Bennette, MPH, Ph.D., K12 Patient-Centered Outcomes Research Scholar, Group Health Research Institute, University of WashingtonOur team at the University of Washington recently developed a decision-analytic policy model to evaluate the potential clinical and economic impact of returning ACMG-recommended incidental findings from next-generation sequencing. We found that returning incidental findings is likely cost effective for certain patient populations receiving next-generation sequencing, but that screening of generally healthy individuals is likely not cost effective based on current data and sequencing costs. We describe the development of our policy model, summarize key findings and discuss future research directions.


MEDIA PARTNERS

Co-Sponsored by: Sponsoring Organization: Lead Sponsoring Publications: Web Partners:Sponsoring Publications:

8:35 Case Studies and Case Series of Genomic/Precision Medicine in a Large Children’s HospitalStephen F. Kingsmore, MB, ChB, BAO, D.Sc., FRCPath, Executive Director, Panomic Medicine, Children’s Mercy – Kansas CityOver 5400 single-gene diseases are known, affecting 4-8% of children. Genome and exome sequencing are starting to change the approach to patient management in these diseases, specifically regarding early etiologic diagnosis and “N-of-1-genome” treatment strategies. Six large retrospective case studies have been or soon will be published providing the first measurements of costs and benefits of genomic/precision medicine in neurodevelopmental disorders and acutely ill infants. Two individual patient cases illustrate the transformative potential of genomic/precision medicine.

9:05 The Evaluation of the Patient Presenting with Symptoms of Obstructive Coronary Artery Disease: Clinical Validity, Clinical Utility and Economic Utility of a Blood-Based Test Incorporating Age, Sex and Gene ExpressionMark Monane, M.D., CMO, CardioDxPatients with symptoms suggestive of obstructive coronary artery disease (CAD) frequently undergo unnecessary testing and procedures. Approximately $6.7 billion/year is spent on non-invasive and invasive testing in the U.S. in the non-diabetic population with no prior revascularization or myocardial infarction, yet some patients continue to be misdiagnosed. We present data on a blood test for use in the evaluation of obstructive CAD among symptomatic patients. Data of clinical validity (96% NPV), clinical utility (multiple change behavior studies) and economic utility (cost implications) will be presented.


10:05 Coffee Break in the Exhibit Hall with Poster Viewing

10:45 Myths and Realities of Clinical GenomicsDavid W. Moskowitz, M.D., Chairman, CEO, CMO & CSO, GenoMed, Inc.Much of what passes for clinical genomics has been a waste of time and money, guided by unrealistic clinical paradigms. This has been fine, because the healthcare system is fundamentally anti-innovative, and is happy to waste the public’s time and money. But for anybody who wants to capture marketshare, it is helpful to review what does and doesn’t work.

11:15 PANEL DISCUSSION: Reimbursement for Genomic Sequencing Services in a Time of Changing Healthcare Business ModelsAt a time when payers are asking themselves, “Why pay for sequencing services?” come meet the people who are successfully crafting reimbursement arguments for the payers in disease areas as diverse as inherited genetic diseases and oncology. Find out the tactics that are working and why.Moderator: Katherine Tynan, Ph.D., Tynan Consulting LLCPanelists: Stephen F. Kingsmore, MB, ChB, BAO, D.Sc., Children’s Mercy – Kansas CityDavid W. Moskowitz, M.D., GenoMed, Inc.Additional Panelists to be Announced

12:00 pm Session Break

12:15 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

Big Data Analytics for Healthcare1:30 Chairperson’s RemarksJohn E. Mattison, M.D., Chief Medical Information Officer, Assistant Medical Director, Southern California Medical Group, Kaiser Permanente

»1:35 FEATURED PRESENTATION: IMPACTING HEALTHCARE WITH DATA ANALYSIS - PERSPECTIVES IN DRUG DISCOVERY, GENOMICS AND WEARABLES

Somalee Datta, Ph.D., Director, Bioinformatics, Stanford Center for Genomics & Personalized Medicine, Stanford University School of MedicineIn healthcare, we have an ever-increasing pile of data (aka, Data Tsunami, our favorite cliché). In the last two decades, we have also made tremendous strides in our computational bandwidth. We even found Higgs! What are the challenges with our healthcare data given the existing computational bandwidth?

2:05 Potential Clinical Genomics Applications in ChinaBill Zheng, Ph.D., Director, Bioinformatics Section, Institute of Genetic Engineering, Southern Medical UniversityNext-generation sequencing and microarrays are being extended to clinical diagnosis. Disease can be diagnosed more efficiently and effectively, and the Chinese market has huge innovations in translational medicine. We present the marketing expansion in clinical medicine as well as in health management in China, plus developments in data mining and data management.


3:05 Refreshment Break in the Exhibit Hall with Poster Viewing

3:45 PatientsLikeMe: A Social Network and a Research Platform for Patient-Reported DataMarcia M. Nizzari, MS, Vice President, Engineering, PatientsLikeMe, Inc.With over 300,000 users, 2,300 conditions and 25 million+ medical datapoints collected, PatientsLikeMe provides a rich source of patient-reported phenotypic data. Patient-reported data provide key input into many areas of healthcare; clinical, payer, pharmaceutical and outcomes research will be positively disrupted by this new source of valuable information. This talk covers existing and proposed uses of those data to drive insights through integration with EHR, NGS data and other sources of -omics data.

»4:15 FEATURED PRESENTATION: THE ONCOSCAPE APPLICATION IN CANCER BIG DATA ANALYSIS

Eric Holland, M.D., Ph.D., Director, Solid Tumor Translational Research, Fred Hutchinson Cancer Research CenterWe have developed a tool for visualization of combined clinical/molecular data for cancer patients. This tool has been used to interrogate multiple public and private datasets for molecular contributions to clinical behavior.

4:45 PANEL DISCUSSION: Analytics and Reality: The Looming Blurring of Boundaries between Genome and Phenome in Health and Disease: Implications for Ontologies and Landing ZonesTo maximize the clinical utility of genomic sequencing data, clinicians must ensure that both genomic and phenomic data is successfully integrated into the electronic health record (EHR) and other patient-centered platforms. This in turn requires understanding of technical infrastructure, security issues, policy requirements and the nature of the data itself. Learn about these topics and more from this panel of experts.Panelists: Becky Swain, Entrepreneur & Founding Member, Cloud Security AllianceJohn E. Mattison, M.D., Chief Medical Information Officer, Assistant Medical Director, Southern California Medical Group, Kaiser PermanenteAdditional Panelists to be Announced

5:30 Close of Conference


HOTEL & TRAVELConference Venue and Hotel:

Hotel Kabuki1625 Post StreetSan Francisco, CA 94115Phone: 415-922-3200

Reservations: Go to the travel page of clinicalgenomeconference.com

Discounted Room Rate: $189 s/dDiscounted Room Rate Cut-off Date: May 25, 2015

Go to the travel page of clinicalgenomeconference.com for additional info

Podium Presentations — Available within Main Agenda! Showcase your solutions to a guaranteed, targeted audience. Package includes a 15- or 30-minute podium presentation within the scientific agenda, exhibit space, on-site branding, access to cooperative marketing efforts by CHI, and more.

Breakfast & Luncheon Podium PresentationsOpportunity includes a 30-minute podium presentation. Meals are delivered to delegates in main session room, which guarantees audience and participation. A limited number of presentations are available for sponsorship and they will sell out quickly. Sign on early to secure your talk!

Invitation-Only VIP Dinner/Hospitality Suite Sponsors will select their top prospects from the conference pre-registration list for an evening of networking at the hotel or at a choice local venue. CHI will extend invitations and deliver prospects, helping you to make the most out of this invaluable opportunity. Evening will be customized according to sponsor’s objectives i.e.:• Purely social• Focus group• Reception style• Plated dinner with specific conversation focus

ExhibitExhibitors will enjoy facilitated networking opportunities with qualified delegates. Speak face-to-face with prospective clients and showcase your latest product, service, or solution.

Additional branding and sponsorship opportunities available, including:• Conference Tote Bags• Badge Lanyards• Program Guide Advertisement• Literature Distribution (Tote Bag Insert or Chair Drop)

Looking for additional ways to drive leads to your sales team? CHI’s Lead Generation Programs will help you obtain more targeted, quality leads throughout the year. We will mine our database of 800,000+ life science professionals to your specific needs. We guarantee a minimum of 100 leads per program! Opportunities include:• Whitepapers • Web Symposia• Custom Market Research Surveys• Podcasts

SPONSORSHIP, EXHIBIT, AND LEAD GENERATION OPPORTUNITIESCHI offers comprehensive sponsorship packages which include presentation opportunities, exhibit space, branding and networking with specific prospects. Sponsorship allows you to achieve your objectives before, during, and long after the event. Any sponsorship can be customized to meet your company’s needs and budget. Signing on early will allow you to maximize exposure to qualified decision-makers.

INFORMATION

For sponsorship, exhibit and lead generation information, please contact:Elizabeth Lemelin | Business Development Manager781-972-1342 | [email protected]


the 4th annualclinical genome tcgc … · new york genome center nathan d. price, ... 4:00...

Documents